Seçkin Dereli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seçkin Dereli has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Ahmet Kaya
Deparment of Cardiology, Faculty of Medicine, Ordu University, Ordu, Turkey
9 shared publications- Mustafa Yenerçağ
Department of Cardiology, Samsun University, Samsun Education and Research Hospital, Samsun, Türkiye
5 shared publications - Onur Osman Şeker
Department of Cardiology Samsun Education and Research Hospital Samsun Turkey
4 shared publications - Sinan Cerşit
Kartal Koşuyolu Heart Training and Research Hospital, Department of Cardiology, İstanbul, Turkey. Electronic correspondence:
4 shared publications Adil Bayramoğlu
Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey
3 shared publications- Adil Bayramoğlu
Department of Cardiology Faculty of Medicine Inonu University Malatya Turkey
3 shared publications
Latest Publications
- 1 November 2026
- Published by JLE in Magnesium Research
- Vol. 39 (1) , 33-48
Effect of magnesium bisglycinate following coronary syndrome in young adults: a retrospective cohort study of self-reported sleep quality, anxiety symptoms, and depressive symptoms
Background/Objective Anxiety, depression, and poor sleep are common after acute coronary syndrome (ACS) and adversely affect prognosis, yet treatment options are limited. Oral magnesium bisglycinate improves sleep and mood in non-cardiac populations but has not been studied following ACS. We investigated whether post-discharge magnesium bisglycinate use is associated with improvement in self-reported sleep quality and anxiety and depressive symptom scores. Methods In this single-centre retrospective cohort, 120 patients (68 magnesium, 52 comparator) were followed for three months after ACS. Magnesium bisglycinate (240 mg elemental magnesium daily) was initiated at the first post-discharge visit. The primary outcome was sleep quality (Pittsburgh Sleep Quality Index, PSQI); anxiety (Beck Anxiety Inventory, BAI) and depression (Beck Depression Inventory, BDI) were secondary outcomes, assessed with serum magnesium at baseline and three months. Results Baseline characteristics were comparable. At three months, the magnesium group showed greater improvement in self-reported sleep quality (PSQI: 5.2 ± 2.6 vs 7.3 ± 3.1; p < 0.001), anxiety (BAI: 12.1 ± 4.9 vs 15.8 ± 5.3; p < 0.001), and depressive symptoms (BDI: 8.3 ± 4.7 vs 11.2 ± 5.5; p = 0.003), with Cohen’s d = 0.57–0.74. Serum magnesium did not differ between groups at either time point (p = 0.55 and p = 0.20), and the associations persisted after multivariable adjustment and in sensitivity models including baseline serum magnesium, renal function, and medications affecting magnesium balance. Conclusion Post- discharge magnesium bisglycinate use was associated with greater improvement in self-reported sleep, anxiety, and depressive symptom scores following ACS. These hypothesis-generating findings, limited by residual confounding and healthy-user bias, require confirmation in an adequately powered randomized controlled trial.
- 1 November 2026
- Published by JLE in Magnesium Research
- Vol. 39 (1) , 33-48
Effect of magnesium bisglycinate following coronary syndrome in young adults: a retrospective cohort study of self-reported sleep quality, anxiety symptoms, and depressive symptoms
Background/Objective Anxiety, depression, and poor sleep are common after acute coronary syndrome (ACS) and adversely affect prognosis, yet treatment options are limited. Oral magnesium bisglycinate improves sleep and mood in non-cardiac populations but has not been studied following ACS. We investigated whether post-discharge magnesium bisglycinate use is associated with improvement in self-reported sleep quality and anxiety and depressive symptom scores. Methods In this single-centre retrospective cohort, 120 patients (68 magnesium, 52 comparator) were followed for three months after ACS. Magnesium bisglycinate (240 mg elemental magnesium daily) was initiated at the first post-discharge visit. The primary outcome was sleep quality (Pittsburgh Sleep Quality Index, PSQI); anxiety (Beck Anxiety Inventory, BAI) and depression (Beck Depression Inventory, BDI) were secondary outcomes, assessed with serum magnesium at baseline and three months. Results Baseline characteristics were comparable. At three months, the magnesium group showed greater improvement in self-reported sleep quality (PSQI: 5.2 ± 2.6 vs 7.3 ± 3.1; p < 0.001), anxiety (BAI: 12.1 ± 4.9 vs 15.8 ± 5.3; p < 0.001), and depressive symptoms (BDI: 8.3 ± 4.7 vs 11.2 ± 5.5; p = 0.003), with Cohen’s d = 0.57–0.74. Serum magnesium did not differ between groups at either time point (p = 0.55 and p = 0.20), and the associations persisted after multivariable adjustment and in sensitivity models including baseline serum magnesium, renal function, and medications affecting magnesium balance. Conclusion Post- discharge magnesium bisglycinate use was associated with greater improvement in self-reported sleep, anxiety, and depressive symptom scores following ACS. These hypothesis-generating findings, limited by residual confounding and healthy-user bias, require confirmation in an adequately powered randomized controlled trial.
- Open Access
- 23 September 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (9) , e70473
Long‐Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3–4 Chronic Kidney Disease: A 24‐Month Single‐Centre Cohort
Background: Stage 3–4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor–neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V). Hypothesis: We hypothesized that, over 24 months, S/V would be associated with stable renal function and acceptable clinical outcomes; the study was designed to be descriptive rather than comparative. Methods: We retrospectively analyzed 360 adults with HFrEF (LVEF < 40%) and predialysis stage 3–4 CKD who initiated S/V (2017–2023) and were followed for up to 24 months; decedents were analyzed as events, not excluded. The primary renal composite (sustained ≥ 30% eGFR decline, chronic dialysis, or end‐stage kidney disease) was analyzed with competing‐risk methods (Aalen–Johansen and Fine–Gray, with death competing); mortality with Cox regression; longitudinal eGFR with mixed‐effects; and sparse‐event models with Firth penalization. Results: Among survivors, mean eGFR was stable (mixed‐model slope non‐significant), with no creatinine rise; NT‐proBNP and CRP fell (both p < 0.001) and NYHA class improved. The renal composite occurred in 12/360 (3.3%); all‐cause and cardiovascular mortality were 6.1% and 3.9%. Lower baseline eGFR was associated with the renal composite. Analyzes of maintenance dose and concomitant SGLT2‐inhibitor use were confounded by treatment tolerance and calendar era and were hypothesis‐generating only. Conclusions: In this single‐arm cohort of HFrEF with stage 3–4 CKD, S/V was generally well tolerated, with stable renal function and low event rates over 24 months. These descriptive, hypothesis‐generating findings cannot establish comparative benefit and require confirmation in controlled studies.
- 23 September 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (9) , e70473
Open AccessLong‐Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3–4 Chronic Kidney Disease: A 24‐Month Single‐Centre Cohort
Background: Stage 3–4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor–neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V). Hypothesis: We hypothesized that, over 24 months, S/V would be associated with stable renal function and acceptable clinical outcomes; the study was designed to be descriptive rather than comparative. Methods: We retrospectively analyzed 360 adults with HFrEF (LVEF < 40%) and predialysis stage 3–4 CKD who initiated S/V (2017–2023) and were followed for up to 24 months; decedents were analyzed as events, not excluded. The primary renal composite (sustained ≥ 30% eGFR decline, chronic dialysis, or end‐stage kidney disease) was analyzed with competing‐risk methods (Aalen–Johansen and Fine–Gray, with death competing); mortality with Cox regression; longitudinal eGFR with mixed‐effects; and sparse‐event models with Firth penalization. Results: Among survivors, mean eGFR was stable (mixed‐model slope non‐significant), with no creatinine rise; NT‐proBNP and CRP fell (both p < 0.001) and NYHA class improved. The renal composite occurred in 12/360 (3.3%); all‐cause and cardiovascular mortality were 6.1% and 3.9%. Lower baseline eGFR was associated with the renal composite. Analyzes of maintenance dose and concomitant SGLT2‐inhibitor use were confounded by treatment tolerance and calendar era and were hypothesis‐generating only. Conclusions: In this single‐arm cohort of HFrEF with stage 3–4 CKD, S/V was generally well tolerated, with stable renal function and low event rates over 24 months. These descriptive, hypothesis‐generating findings cannot establish comparative benefit and require confirmation in controlled studies.
- Open Access
- 19 August 2026
- Published by Galenos Yayinevi in Interventional Cardiology Perspectives
BIO-PCI: DCB-First Revascularization with Multidisciplinary Secondary Prevention in Young Patients—A Retrospective Cohort Study
BIO-PCI: DCB-First Revascularization with Multidisciplinary Secondary Prevention in Young Patients—A Retrospective Cohort Study - Interventional Cardiology Perspectives
- 19 August 2026
- Published by Galenos Yayinevi in Interventional Cardiology Perspectives
Open AccessBIO-PCI: DCB-First Revascularization with Multidisciplinary Secondary Prevention in Young Patients—A Retrospective Cohort Study
BIO-PCI: DCB-First Revascularization with Multidisciplinary Secondary Prevention in Young Patients—A Retrospective Cohort Study - Interventional Cardiology Perspectives
- 1 July 2026
- Published by JLE in Magnesium Research
- Vol. 38 (4) , 118-125
Effects of magnesium taurate-potassium citrate on blood pressure and vascular stiffness in low-risk adults with elevated blood pressure
Elevated blood pressure (BP) is a key modifiable cardiovascular risk factor. In low-risk individuals, guidelines recommend lifestyle interventions before pharmacotherapy. Evidence for magnesium taurate-potassium citrate supplementation in this setting is lacking. This prospective, single-arm observational study enrolled 121 adults with elevated BP or stage 1 hypertension and low cardiovascular risk (SCORE2/SCORE2-OP), per 2024 ESC guidelines, who declined antihypertensive drugs. All received lifestyle counselling plus magnesium taurate-potassium citrate (121 mg elemental magnesium, 180 mg elemental potassium daily) for three months. The per-protocol cohort included 110 patients. Primary outcomes were BP changes at work, at home (HBPM), and ambulatory BP (ABPM). Secondary outcomes were pulse-wave velocity (PWV), augmentation index (AIx), renal function, and serum electrolytes. At three months, BP at work fell by -12/-9 mmHg, HBPM by -11/-8 mmHg, and ABPM by -11/-8 mmHg (all p<0.001). PWV and AIx improved by -0.9 m/s and -4.0% (p<0.001). Serum magnesium rose by +0.1 mg/dL (p=0.003) without changes in sodium, potassium, or renal function. No serious adverse events occurred. In low-risk adults with elevated BP, magnesium taurate-potassium citrate plus lifestyle advice significantly reduced BP and arterial stiffness over three months, supporting magnesium taurate-potassium citrate as a safe non-pharmacological option. As this was a single-arm observational study with routine lifestyle counselling, causal inference was limited, underscoring the need for randomized trials.
- 1 July 2026
- Published by JLE in Magnesium Research
- Vol. 38 (4) , 118-125
Effects of magnesium taurate-potassium citrate on blood pressure and vascular stiffness in low-risk adults with elevated blood pressure
Elevated blood pressure (BP) is a key modifiable cardiovascular risk factor. In low-risk individuals, guidelines recommend lifestyle interventions before pharmacotherapy. Evidence for magnesium taurate-potassium citrate supplementation in this setting is lacking. This prospective, single-arm observational study enrolled 121 adults with elevated BP or stage 1 hypertension and low cardiovascular risk (SCORE2/SCORE2-OP), per 2024 ESC guidelines, who declined antihypertensive drugs. All received lifestyle counselling plus magnesium taurate-potassium citrate (121 mg elemental magnesium, 180 mg elemental potassium daily) for three months. The per-protocol cohort included 110 patients. Primary outcomes were BP changes at work, at home (HBPM), and ambulatory BP (ABPM). Secondary outcomes were pulse-wave velocity (PWV), augmentation index (AIx), renal function, and serum electrolytes. At three months, BP at work fell by -12/-9 mmHg, HBPM by -11/-8 mmHg, and ABPM by -11/-8 mmHg (all p<0.001). PWV and AIx improved by -0.9 m/s and -4.0% (p<0.001). Serum magnesium rose by +0.1 mg/dL (p=0.003) without changes in sodium, potassium, or renal function. No serious adverse events occurred. In low-risk adults with elevated BP, magnesium taurate-potassium citrate plus lifestyle advice significantly reduced BP and arterial stiffness over three months, supporting magnesium taurate-potassium citrate as a safe non-pharmacological option. As this was a single-arm observational study with routine lifestyle counselling, causal inference was limited, underscoring the need for randomized trials.
- Open Access
- 2 January 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 351-354
Real-World Diagnostic and Therapeutic Insights in Transthyretin Cardiac Amyloidosis: Experience from the Black Sea Region of Türkiye
- 2 January 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 351-354
Open AccessReal-World Diagnostic and Therapeutic Insights in Transthyretin Cardiac Amyloidosis: Experience from the Black Sea Region of Türkiye
- 10 December 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (1) , 6
Can sacubitril/valsartan enhance sleep quality and reduce daytime dysfunction in HFrEF patients?
Introduction Congestive heart failure (CHF) affects 65 million people worldwide, with significant prevalence among the elderly. Despite therapeutic advancements, CHF often coexists sleep disorder, impacting morbidity and mortality. Optimizing heart failure management is crucial, especially in light of recent debates on respiratory therapies for heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan (SV) has shown promise in reducing cardiovascular mortality and hospital readmissions, though its impact on sleep is less explored. Methods This prospective, cohort, open-label study evaluated HFrEF patients with LVEF < 40%, NYHA class II-IV, and optimized medical management. Exclusions included sleep apnea, primary insomnia, or psychiatric conditions. Patients transitioned from ACE inhibitors or ARBs to SV, with dose adjustments and biweekly clinical assessments. Sleep quality and daytime alertness were measured using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) at baseline and after reaching the target dosage of SV. Functional capacity was assessed via the six-minute walk test (6-MWT). Results Over a mean follow-up of 132 ± 31 days, adjusted analyses showed improvement in PSQI (β − 2.60, 95% CI − 3.20 to − 2.00; p < 0.001) and ESS (β − 3.10, − 3.80 to − 2.40; p < 0.001), with increases in LVEF (+ 6.8 pp, + 5.2 to + 8.3; p < 0.001) and 6-MWT (+ 96 m, + 35 to + 157; p = 0.002); odds of PSQI > 5 and ESS ≥ 11 at follow-up were lower (OR 0.30, 0.18–0.48; p < 0.001 and OR 0.25, 0.11–0.52; p = 0.001; Table 3, and 4). Conclusion SV improves sleep quality, reduces daytime dysfunction, and enhances exercise capacity in HFrEF patients, indicating potential dual therapeutic benefits. Further studies are needed to explore SV’s full impact on sleep parameters and quality of life in this high-risk group.
- 10 December 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (1) , 6
Can sacubitril/valsartan enhance sleep quality and reduce daytime dysfunction in HFrEF patients?
Introduction Congestive heart failure (CHF) affects 65 million people worldwide, with significant prevalence among the elderly. Despite therapeutic advancements, CHF often coexists sleep disorder, impacting morbidity and mortality. Optimizing heart failure management is crucial, especially in light of recent debates on respiratory therapies for heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan (SV) has shown promise in reducing cardiovascular mortality and hospital readmissions, though its impact on sleep is less explored. Methods This prospective, cohort, open-label study evaluated HFrEF patients with LVEF < 40%, NYHA class II-IV, and optimized medical management. Exclusions included sleep apnea, primary insomnia, or psychiatric conditions. Patients transitioned from ACE inhibitors or ARBs to SV, with dose adjustments and biweekly clinical assessments. Sleep quality and daytime alertness were measured using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) at baseline and after reaching the target dosage of SV. Functional capacity was assessed via the six-minute walk test (6-MWT). Results Over a mean follow-up of 132 ± 31 days, adjusted analyses showed improvement in PSQI (β − 2.60, 95% CI − 3.20 to − 2.00; p < 0.001) and ESS (β − 3.10, − 3.80 to − 2.40; p < 0.001), with increases in LVEF (+ 6.8 pp, + 5.2 to + 8.3; p < 0.001) and 6-MWT (+ 96 m, + 35 to + 157; p = 0.002); odds of PSQI > 5 and ESS ≥ 11 at follow-up were lower (OR 0.30, 0.18–0.48; p < 0.001 and OR 0.25, 0.11–0.52; p = 0.001; Table 3, and 4). Conclusion SV improves sleep quality, reduces daytime dysfunction, and enhances exercise capacity in HFrEF patients, indicating potential dual therapeutic benefits. Further studies are needed to explore SV’s full impact on sleep parameters and quality of life in this high-risk group.
- 2 December 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 124, 272-282
Predictive Value of Liver Fibrosis Index-4 for Clinical Outcomes Following Carotid Artery Stenting
- 2 December 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 124, 272-282
Predictive Value of Liver Fibrosis Index-4 for Clinical Outcomes Following Carotid Artery Stenting
- 15 October 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 123, 247-259
Prognostic Value of the Fibrosis-5 Index for Predicting 2-Year Adverse Outcomes in Patients With Peripheral Artery Disease Undergoing Endovascular Intervention
- 15 October 2025
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 123, 247-259
Prognostic Value of the Fibrosis-5 Index for Predicting 2-Year Adverse Outcomes in Patients With Peripheral Artery Disease Undergoing Endovascular Intervention
- Open Access
- 29 September 2025
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 22 (3) , 418-425
Endovasküler Girişim Uygulanan Periferik Arter Hastalarında MELD-Albumin Skorunun Öngörücü Değeri: İki Yıllık Takip
Amaç: Periferik arter hastalığı (PAH), sistemik aterosklerozun bir yansıması olup, hastaları hem majör advers kardiyak olaylar (MACE) hem de majör advers ekstremite olayları (MALE) açısından yüksek risk altında bırakmaktadır. Bu çalışmanın temel amacı, endovasküler girişim uygulanan bu yüksek riskli hasta popülasyonunda, rutin kan tetkiklerinden kolayca hesaplanabilen MELD-XI ve MELD-Albumin skorlarının, 24 aylık takipte MACE ve MALE'i öngörmedeki prognostik gücünü karşılaştırmalı olarak değerlendirmek ve bu skorların klinik karar mekanizmalarındaki potansiyel yerini aydınlatmaktır. Materyal ve metod: Çalışmamız, 2018 ile 2022 yılları arasında kliniğimizde alt ekstremite PAH tanısıyla endovasküler girişim uygulanmış 427 hastanın verilerinin retrospektif olarak analiz edildiği bir kohort çalışmasıdır. Hastalar, MELD-Albumin skorlarına göre beş eşit gruba (quintile) ayrılmıştır. Birincil sonlanım noktaları, 24 aylık takip süresince gelişen MACE (kardiyovasküler ölüm, ölümcül olmayan miyokart enfarktüsü, ölümcül olmayan inme) ve MALE (majör ampütasyon, tekrar endovasküler veya cerrahi revaskülarizasyon) olarak tanımlanmıştır. Skorların ayırt edicilik kapasiteleri Alıcı İşletim Karakteristiği (ROC) eğrisi analizi ile, bağımsız öngördürücü rolleri ise çok değişkenli Cox regresyon analizi ile incelenmiştir. Bulgular: Çalışma popülasyonumuzda, MELD-Albumin skoru arttıkça hastaların demografik ve klinik risk profillerinin ağırlaştığı gözlenmiştir. Yüksek MELD-Albumin skoruna sahip gruplarda ileri yaş, diyabet, hipertansiyon, kronik böbrek hastalığı ve daha karmaşık lezyon morfolojisi gibi faktörler istatistiksel olarak anlamlı düzeyde daha yaygındı (tümü için p<0.001). Klinik takip neticesinde, en yüksek MELD-Albumin skoruna sahip beşinci gruptaki (Q5) hastaların, en düşük skorlu gruba (Q1) kıyasla hem MACE hem de MALE oranlarının dramatik şekilde arttığı saptanmıştır (kardiyovasküler ölüm için %26.8'e karşılık %2.7; majör amputasyon için %18.6'ya karşılık %6.0; p<0.001). Prognostik performans analizinde, MELD-Albumin skorunun MACE'i öngörmede (Eğri Altında Kalan Alan [AUC]: 0.872; %95 GA: 0.785-0.892) ve MALE'i öngörmede (AUC: 0.803; %95 GA: 0.739-0.869) MELD-XI skoruna (sırasıyla AUC: 0.723 ve 0.583) kıyasla istatistiksel olarak anlamlı derecede üstün bir öngörü gücüne sahip olduğu kanıtlanmıştır. Cox regresyon analizi, MELD-Albumin skorunun yaş, diyabet ve diğer bilinen risk faktörlerinden bağımsız olarak hem MACE hem de MALE için güçlü bir bağımsız belirteç olduğunu ortaya koymuştur (p<0.001). Sonuç: MELD-Albumin skoru, karaciğer-böbrek aksının fonksiyonel durumunu ve hastanın nutrisyonel/enflamatuar statüsünü yansıtan biyobe-lirteçleri bir araya getirerek, endovasküler tedavi uygulanan PAH hastalarında gelecekteki kardiyovasküler ve ekstremiteye bağlı olumsuz olayları öngörmede basit, maliyet-etkin ve güçlü bir prognostik araçtır. Bulgularımız, bu skorun MELD-XI'e kıyasla daha üstün bir performansa sahip olduğunu ve klinisyenlerin risk sınıflandırması yaparak tedavi stratejilerini bireyselleştirmelerine yardımcı olabileceğini güçlü bir şekilde desteklemektedir. Anahtar Kelimeler: MELD-Albumin Skoru, Periferik Arter Hastalığı, Endovasküler Girişim, Majör Advers Kardiyak Olaylar, Majör Advers Ekstremite Olayları, Prognoz
- 29 September 2025
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 22 (3) , 418-425
Open AccessEndovasküler Girişim Uygulanan Periferik Arter Hastalarında MELD-Albumin Skorunun Öngörücü Değeri: İki Yıllık Takip
Amaç: Periferik arter hastalığı (PAH), sistemik aterosklerozun bir yansıması olup, hastaları hem majör advers kardiyak olaylar (MACE) hem de majör advers ekstremite olayları (MALE) açısından yüksek risk altında bırakmaktadır. Bu çalışmanın temel amacı, endovasküler girişim uygulanan bu yüksek riskli hasta popülasyonunda, rutin kan tetkiklerinden kolayca hesaplanabilen MELD-XI ve MELD-Albumin skorlarının, 24 aylık takipte MACE ve MALE'i öngörmedeki prognostik gücünü karşılaştırmalı olarak değerlendirmek ve bu skorların klinik karar mekanizmalarındaki potansiyel yerini aydınlatmaktır. Materyal ve metod: Çalışmamız, 2018 ile 2022 yılları arasında kliniğimizde alt ekstremite PAH tanısıyla endovasküler girişim uygulanmış 427 hastanın verilerinin retrospektif olarak analiz edildiği bir kohort çalışmasıdır. Hastalar, MELD-Albumin skorlarına göre beş eşit gruba (quintile) ayrılmıştır. Birincil sonlanım noktaları, 24 aylık takip süresince gelişen MACE (kardiyovasküler ölüm, ölümcül olmayan miyokart enfarktüsü, ölümcül olmayan inme) ve MALE (majör ampütasyon, tekrar endovasküler veya cerrahi revaskülarizasyon) olarak tanımlanmıştır. Skorların ayırt edicilik kapasiteleri Alıcı İşletim Karakteristiği (ROC) eğrisi analizi ile, bağımsız öngördürücü rolleri ise çok değişkenli Cox regresyon analizi ile incelenmiştir. Bulgular: Çalışma popülasyonumuzda, MELD-Albumin skoru arttıkça hastaların demografik ve klinik risk profillerinin ağırlaştığı gözlenmiştir. Yüksek MELD-Albumin skoruna sahip gruplarda ileri yaş, diyabet, hipertansiyon, kronik böbrek hastalığı ve daha karmaşık lezyon morfolojisi gibi faktörler istatistiksel olarak anlamlı düzeyde daha yaygındı (tümü için p<0.001). Klinik takip neticesinde, en yüksek MELD-Albumin skoruna sahip beşinci gruptaki (Q5) hastaların, en düşük skorlu gruba (Q1) kıyasla hem MACE hem de MALE oranlarının dramatik şekilde arttığı saptanmıştır (kardiyovasküler ölüm için %26.8'e karşılık %2.7; majör amputasyon için %18.6'ya karşılık %6.0; p<0.001). Prognostik performans analizinde, MELD-Albumin skorunun MACE'i öngörmede (Eğri Altında Kalan Alan [AUC]: 0.872; %95 GA: 0.785-0.892) ve MALE'i öngörmede (AUC: 0.803; %95 GA: 0.739-0.869) MELD-XI skoruna (sırasıyla AUC: 0.723 ve 0.583) kıyasla istatistiksel olarak anlamlı derecede üstün bir öngörü gücüne sahip olduğu kanıtlanmıştır. Cox regresyon analizi, MELD-Albumin skorunun yaş, diyabet ve diğer bilinen risk faktörlerinden bağımsız olarak hem MACE hem de MALE için güçlü bir bağımsız belirteç olduğunu ortaya koymuştur (p<0.001). Sonuç: MELD-Albumin skoru, karaciğer-böbrek aksının fonksiyonel durumunu ve hastanın nutrisyonel/enflamatuar statüsünü yansıtan biyobe-lirteçleri bir araya getirerek, endovasküler tedavi uygulanan PAH hastalarında gelecekteki kardiyovasküler ve ekstremiteye bağlı olumsuz olayları öngörmede basit, maliyet-etkin ve güçlü bir prognostik araçtır. Bulgularımız, bu skorun MELD-XI'e kıyasla daha üstün bir performansa sahip olduğunu ve klinisyenlerin risk sınıflandırması yaparak tedavi stratejilerini bireyselleştirmelerine yardımcı olabileceğini güçlü bir şekilde desteklemektedir. Anahtar Kelimeler: MELD-Albumin Skoru, Periferik Arter Hastalığı, Endovasküler Girişim, Majör Advers Kardiyak Olaylar, Majör Advers Ekstremite Olayları, Prognoz
- Open Access
- 17 September 2025
- Published by Springer Nature in Research Square
Comparative Real-World Effectiveness of Sacubitril/Valsartan and SGLT2 Inhibitors in Patients with HFrEF: A Retrospective Cohort Study
Purpose Sacubitril/valsartan (S/V) and SGLT2 inhibitors (SGLT2i) are guideline-recommended (Class I) for HFrEF, yet direct comparative data are limited. We evaluated their relative effectiveness in routine care. Methods Retrospective cohort of 626 HFrEF patients (LVEF ≤ 40%) followed 2017–2024, all with ≥ 12 months of optimized β-blocker and RAAS inhibition. Three strategies: Group 1 (n = 200) ACEI/ARB→S/V; Group 2 (n = 190) ACEI/ARB→+SGLT2i (often because of S/V affordability); Group 3 (n = 220) on S/V then + SGLT2i. Outcomes were compared in the 12 months before (T0) and after (T1) treatment change. Results Switching to S/V was associated with greater improvement than adding SGLT2i to ACEI/ARB. HF hospitalizations fell 61% (1.8→0.7 per patient-year; p < 0.001) with S/V vs 25% (1.6→1.2; p = 0.048) with SGLT2i. NT-proBNP decreased 48% (1820→940 pg/mL; p < 0.001) with S/V vs 15% (2395→2020; p = 0.047) with SGLT2i. LVEF rose by 7.1% (28.7→35.8%; p < 0.001) with S/V vs 2.3% (30.5→32.8%; p = 0.06) with SGLT2i. Outpatient visits and emergency department admissions showed parallel reductions. Adding SGLT2i on background S/V (Group 3) provided modest incremental benefits, particularly for visits and NYHA class. Conclusions In well-treated HFrEF, initiating S/V after ACEI/ARB was linked to larger gains across hospitalizations, biomarkers, and function than adding SGLT2i to ACEI/ARB, while SGLT2i on top of S/V offered smaller complementary improvements. These real-world data support S/V as the backbone therapy, with SGLT2i providing additional—though less pronounced—benefits.
- 17 September 2025
- Published by Springer Nature in Research Square
Open AccessComparative Real-World Effectiveness of Sacubitril/Valsartan and SGLT2 Inhibitors in Patients with HFrEF: A Retrospective Cohort Study
Purpose Sacubitril/valsartan (S/V) and SGLT2 inhibitors (SGLT2i) are guideline-recommended (Class I) for HFrEF, yet direct comparative data are limited. We evaluated their relative effectiveness in routine care. Methods Retrospective cohort of 626 HFrEF patients (LVEF ≤ 40%) followed 2017–2024, all with ≥ 12 months of optimized β-blocker and RAAS inhibition. Three strategies: Group 1 (n = 200) ACEI/ARB→S/V; Group 2 (n = 190) ACEI/ARB→+SGLT2i (often because of S/V affordability); Group 3 (n = 220) on S/V then + SGLT2i. Outcomes were compared in the 12 months before (T0) and after (T1) treatment change. Results Switching to S/V was associated with greater improvement than adding SGLT2i to ACEI/ARB. HF hospitalizations fell 61% (1.8→0.7 per patient-year; p < 0.001) with S/V vs 25% (1.6→1.2; p = 0.048) with SGLT2i. NT-proBNP decreased 48% (1820→940 pg/mL; p < 0.001) with S/V vs 15% (2395→2020; p = 0.047) with SGLT2i. LVEF rose by 7.1% (28.7→35.8%; p < 0.001) with S/V vs 2.3% (30.5→32.8%; p = 0.06) with SGLT2i. Outpatient visits and emergency department admissions showed parallel reductions. Adding SGLT2i on background S/V (Group 3) provided modest incremental benefits, particularly for visits and NYHA class. Conclusions In well-treated HFrEF, initiating S/V after ACEI/ARB was linked to larger gains across hospitalizations, biomarkers, and function than adding SGLT2i to ACEI/ARB, while SGLT2i on top of S/V offered smaller complementary improvements. These real-world data support S/V as the backbone therapy, with SGLT2i providing additional—though less pronounced—benefits.